Clinical Trial Update: Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer [Phase 1]

View source ↗

Summary

A completed Phase 1 trial evaluating the safety of combining SB-485232 (interleukin-18) with Doxil (liposomal doxorubicin) in advanced epithelial ovarian cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• Doxil (liposomal doxorubicin)
• SB-485232

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Ovarian | Phase 1 | Status: COMPLETED